TD Cowen analyst Marc Frahm downgraded Blueprint Medicines (BPMC) to Hold from Buy with a $130 price target after Sanofi (SNY) announced its intention to acquire Blueprint for $9.1B in equity value and up to $9.5B including a contingent value right.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint downgraded to Peer Perform from Outperform at Wolfe Research
- Blueprint Medicines downgraded to Neutral from Overweight at JPMorgan
- Blueprint Medicines downgraded to Perform from Outperform at Oppenheimer
- Blueprint Medicines downgraded to Sector Perform from Outperform at Scotiabank
- Blueprint Medicines downgraded to Hold from Buy at Needham